A very common workflow is to index some data based on its embeddings and then given a new query embedding retrieve the most similar examples with k-Nearest Neighbor search. For example, you can imagine embedding a large collection of papers by their abstracts and then given a new paper of interest retrieve the most similar papers to it.
TLDR in my experience it ~always works better to use an SVM instead of kNN, if you can afford the slight computational hit
We observed that generally the embedding representation is very rich and information dense. For example, reducing the dimensionality of the inputs using SVD or PCA, even by 10%, generally results in worse downstream performance on specific tasks.
The present study investigated mosquito species composition and phenotypic insecticide resistance profile to support decision-making in vector control in the Republic of Djibouti at the Horn of Africa. Adult mosquitoes were collected between December 2016 and December 2017 across 20 sentinel sites established in the 6 regions of the country using both Centers for Disease Control (CDC) miniature light traps and pyrethrum spray catches (PSC). Female mosquitoes were kept aside, for morphological identification to species by an expert entomologist using appropriate taxonomic keys by Gillies & Coetzee and Glick. Bioassays were also conducted in An. stephensi from Djibouti-ville against nine insecticides used in public health. A total number of 12,538 host-seeking mosquitoes belonging to four genera (Anopheles, Culex, Aedes, Uranotaenia) comprising 12 species were collected. Among these, A. gambiae S.L. and A. stephensi were the two major malaria vectors identified while secondary malaria vectors such as A. nili somalicus, A. dthali and A. azaniae were also collected. Culex quinquefasciatus was the most abundant mosquito species in the 6 regions. WHO susceptibility tests performed on A. stephensi population from Djibouti-ville showed resistance to pyrethroids, organophosphates, carbamates and DDT.
In this tutorial we look at the word2vec model by Mikolov et al. This model is used for learning vector representations of words, called "word embeddings".
Inkscape ist ein Open-Source-Vektorgrafikeditor, dessen Fähigkeiten mit denen von Illustrator, Freehand, CorelDraw oder Xara X vergleichbar sind. Inkscape verwendet das vom W3C standardisierte SVG-Dateiformat (Scalable Vector Graphics).
Public-domain (CC0 1.0) collection of SVG icons and hexadecimal color codes for over 200 popular brands. Also includes CSS, LESS, SCSS with color variables, making it a sort of proto-framework.
Revathi. International Journal of Innovative Research in Information Security, 09 (2):
50-54(мая 2023)1. Muhlenbach, F. and Rakotomalala, R. (2015), “Discretization of Continuous Attributes,” In: Wang, J., Ed., Encyclopedia of Data Warehousing and Mining, Idea Group Reference, 397-402. https://doi.org/10.4018/978-1-59140-557-3.ch076 2. M. Liu, D. Zhang, and D. Shen, “Relationship induced multi- 52 template learning for diagnosis of alzheimer’s disease and mild cognitive impairment,” IEEE transactions on medical imaging, vol. 35, no. 6, p. 1463—1474, (2016). https://doi.org/10.1109/tmi.2016.2515021 3. Abdullah Caliskan, Hasan Badem, A. Baştürk, M.E. Yüksel, “Diagnosis Of The Parkinson Disease By Using Deep Neural Network Classifier”, Journal Of Electrical And Electronics Engineering, (2017):3311-3318 4. M. Abdar and M. Zomorodi-Moghadam, “Impact of Patients’ Gender on Parkinson’s disease using Classification Algorithms” Journal of AI and Data Mining, vol. 6, (2018). 5. Sleigh, J.W.; Olofsen, E.; Dahan, A.; de Goede, J.; Steyn-Ross, A. Entropies of the EEG: The effects of general anaesthesia. In Proceedings of the 5th International Conference on Memory, Awareness and Consciousness, New York, NY, USA, 1–3 June (2019) 6. Tsuda, M., Asano, S., Kato, Y., Murai, K., and Miyazaki, M. (2020). Differential diagnosis of multiple system atrophy with predominant parkinsonism and Parkinson's disease using neural networks. J. Neurol. Sci. 401, 19–26. https://doi.org/10.1016/j.jns.2019.04.014 7. Tysnes, O.-B., and Storstein, A. (2021). Epidemiology of Parkinson's disease. J. Neural Trans. 124, 901–905. https://doi:10.1007/s00702-017-1686-y 8. Parkinson J. An Essay on the Shaking Palsy. London: Sherwood, Neely, and Jones; 1817. pp. 1–16. Google Scholar 9. Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson’s disease. Mov Disord. 2003;18:19–31. PubMed Google Scholar 10. National Institute for Health and Care Excellence (NICE) Parkinson’s disease: diagnosis and management in primary and secondary care. NICE clinical guidelines 35. Jun, 2006. Available https://doi.org/10.1136/heartjnl-2022-321095 http://www.nice.org.uk/guidance/cg35/resources/guidance-parkinsons-disease-pdf. Accessed April 28, 2015. 11. Schrag A, Horsfall L, Walters K, et al. Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol. 2015; PubMed Google Scholar https://doi.org/10.1016/s1474-4422(14)70287-x 12. Parkinson’s Disease Foundation Statistics on Parkinson’s. Available at: www.pdf.org.en/parkinson_statistics Accessed June 19, 2014. 13. Driver JA, Logroscino G, Gaziano JM, et al. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology. 2009;72:32–38. PMC free article PubMed Google Scholar https://doi.org/10.1212/01.wnl.0000341769.50075.bb 14. De Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5:525–535. PubMed Google Scholar 15. Miller IN, Cronin-Golomb A. Gender differences in Parkinson’s disease: clinical characteristics and cognition. Mov Disord. 2010;25:2695–2703. PMC free article PubMed Google Scholar https://doi.org/10.1002/mds.23388 16. Rumayor MA, Arrieta O, Sotelo J, et al. Female gender but not cigarette smoking delays the onset of Parkinson’s disease. Clin Neurol Neurosurg. 2009;PubMed Google Scholar https://doi.org/10.1016/j.clineuro.2009.07.012 17. Gómez-Esteban JC, Zarranz JJ, Lezcano E, et al. Influence of motor symptoms upon the quality of life of patients with Parkinson’s disease. Eur Neurol. 2007;57:161–165. PubMed Google Scholar https://doi.org/10.1159/000098468 18. Pennington S, Snell K, Lee M, et al. The cause of death in idiopathic Parkinson’s disease. Parkinsonism Relat Disord. 2010;16:434–437. PubMed Google Scholar https://doi.org/10.1016/j.parkreldis.2010.04.010 19. Jankovic J, Poewe W. Therapies in Parkinson’s disease. Curr Opin Neurol. 2012; PubMed Google Scholar 20. Smith Y, Wichmann T, Factor SA, DeLong MR. Parkinson’s disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsycho pharmacology. 2012;PMC free article PubMed Google Scholar https://doi.org/10.1038/npp.2011.212 21. Simonson W, Hauser RA, Schapira AHV. Role of the pharmacist in the effective management of wearing-off in Parkinson’s disease. Ann Pharmacother.2007; PubMed Google Scholar https://doi.org/10.1345/aph.1k348 22. Van der Marck MA, Bloem BR, Borm GF, et al. Effectiveness of multidisciplinary care for Parkinson’s disease: a randomized, controlled trial. Mov Disord. 2013;PubMed Google Scholar https://doi.org/10.1002/mds.25194 23. Zhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson’s disease: a mechanism of pathogenic and therapeutic significance. Ann NY Acad Sci. 2008;1147:93–104. PMC free article PubMed Google Scholar https://doi.org/10.1196/annals.1427.023 24. Logroscino G. The role of early-life environmental risk factors in Parkinson disease: what is the evidence? Environ Health Perspect. 2005; PMC free article PubMed Google Scholar https://doi.org/10.1289/ehp.7573 25. Spatola M, Wider C. Genetics of Parkinson’s disease: the yield. Parkinsonism Relat Disord. 2014;20(suppl 1):S35–S38. PubMed Google Scholar https://doi.org/10.1016/s1353-8020(13)70011-7 26. Singleton AB, Farer MJ, Bonifati V. The genetics of Parkinson’s disease: progress and therapeutic implications. Mov Disord. 2013;28:14–23. PMC free article Pu bMed Google Scholar https://doi.org/10.1002/mds.25249 27. Santiago JA, Scherzer CR, Potashkin JA. Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson’s disease. PLoS One. 2014; PMC free article PubMed Google Scholar https://doi.org/10.1371/journal.pone.0109042 28. Liu R, Guo X, Park Y, et al. Caffeine intake, smoking, and risk of Parkinson disease in men and women. Am J Epidemiol. 2012; PMC free article PubMed Google Scholar https://doi.org/10.1093/aje/kwr451 29. Benmoyal-Segal L, Soreq H. Gene–environment interactions in sporadic Parkinson’s disease. J Neurochem. 2006;97:1740–1755. PubMed Google Scholar https://doi.org/10.1111/j.1471-4159.2006.03937.x 30. Van der Merwe C, Haylett W, Harvey J, et al. Factors influencing the development of early- or late-onset Parkinson’s disease in a cohort of South African patients. S Afr Med J. 2012;102:848–851. PubMed Google Scholar https://doi.org/10.7196/samj.5879 31. Wang G, Pan J, Chen SD. Kinases and kinase signaling pathways: potential therapeutic targets in Parkinson’s disease. Prog Neurobiol. 2012; PubMed Google Scholar https://doi.org/10.1016/j.pneurobio.2012.06.003 32. Gilgun-Sherki Y, Djaldetti R, Melamed E, Offen D. Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson’s disease. Pharmacogenomics J. 2004;4:291–306. PubMed Google Scholar https://doi.org/10.1038/sj.tpj.6500260 33. Agúndez JA, García-Martín E, Alonso-Navarro H, et al. Anti-Parkinson’s disease drugs and pharmacogenetic considerations. Expert Opin Drug Metab Toxicol. 2013;9:859–874. PubMed Google Scholar https://doi.org/10.1517/17425255.2013.789018 34. Marras C, Goldman SM. Genetics meets environment: evaluating gene–environment interactions in neurologic diseases. Semin Neurol. 2011;31:553–561. PubMed Google Scholar https://doi.org/10.1055/s-0031-1299793 35. Soreq L, Ben-Shaul Y, Israel Z, et al. Meta-analysis of genetic and environmental Parkinson’s disease models reveals a common role of mitochondrial protection pathways. Neurobiol Dis. 2012;45:1018–1030. PubMed Google Scholar https://doi.org/10.1016/j.nbd.2011.12.021 36. Curtin K, Fleckenstein AE, Robison RJ, et al. Methamphetamine/amphetamine abuse and risk of Parkinson’s disease in Utah: a population-based assessment. Drug Alcohol Depend. 2015;146:30–38. PMC free article PubMed Google Scholar https://doi.org/10.1016/j.drugalcdep.2014.10.027 37. Chen JJ, Swope DM. Parkinson’s disease. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: A Pathophysiologic Approach. 9th ed. New York, New York: McGraw-Hill; 2014. Google Scholar 38. Chade AR, Kasten M, Tanner CM. Nongenetic causes of Parkinson’s disease. J Neural Transm Suppl. 2006;70:147–151. PubMed Google Scholar https://doi.org/10.1007/978-3-211-45295-0_23.
L. Li, H. Wang, T. Chin, D. Suter, и S. Zhang. Image and Signal Processing (CISP), 2010 3rd International Congress on, 4, стр. 1586 -1589. (октября 2010)